Seattle-based startup Myosana Therapeutics raised $5M to develop an early-stage candidate treatment for Duchenne muscular dystrophy (DMD).
DMD is caused by mutations in the largest known human gene, dystrophin. Many companies are developing gene therapies to introduce functional dystrophin DNA into cells through adeno-associated viruses (AAVs).
Myosana’s technology develops antibodies that are home to a protein on skeletal and cardiac muscle cells to help deliver genes for repeated use. The company plans to use the funding to identify an early development candidate for DMD by 2025.